NCI-H23人非小细胞肺癌细胞

NCI-H23/NCI-H23细胞系/NCI-H23细胞株/NCI-H23人非小细胞肺癌细胞

Cell line name NCI-H23

Synonyms NCI.H23; NCI H23; H-23; H23; NCIH23

Accession CVCL_1547

Resource Identification Initiative To cite this cell line use: NCI-H23 (RRID:CVCL_1547)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: JFCR39 cancer cell line panel.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI RAS program mutant KRAS cell line panel.

Part of: NCI-60 cancer cell line panel.

Part of: NCI-7 clinical proteomics reference material cell line panel.

Population: African American.

Doubling time: 38 hours (Note=In RPMI 1640 + 10% FBS), 71 hours (Note=In ACL-3), 57 hours (Note=In ACL-3 + BSA) (PubMed=3940644); 25 hours (PubMed=7718330); 35 hours (PubMed=25984343); 39.1 hours (PubMed=29681454); 38 hours (ATCC=CRL-5800); 33.4 hours (NCI-DTP=NCI-H23).

Karyotypic information: Has lost chromosome Y (PubMed=25714623).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Misspelling: H63; PubMed=23381221; PubMed=25120651; Note=Confirmed by author personal communication.

Derived from site: In situ; Lung; UBERON=UBERON_0002048.

PubMed=8626706; DOI=10.1074/jbc.271.19.11477

Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M., Grimley C., Battey J., Mulshine J.L., Cuttitta F.

Insulin-like growth factor expression in human cancer cell lines.

J. Biol. Chem. 271:11477-11483(1996)

 

PubMed=8806092; DOI=10.1002/jcb.240630505

Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.

NCI-Navy Medical Oncology Branch cell line data base.

J. Cell. Biochem. Suppl. 24:32-91(1996)

 

PubMed=10358721; DOI=10.18926/AMO/31626

Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K., Kohara H., Harada M.

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Acta Med. Okayama 53:67-75(1999)

 

PubMed=10536175; DOI=10.3892/ijo.15.5.927

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Int. J. Oncol. 15:927-934(1999)

 

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

 

PubMed=11005564; DOI=10.1038/sj.neo.7900094; PMCID=PMC1550293